Jansman FG - Search Results

1

Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR. Jansman FG, et al. Drug Saf. 2001;24(5):353-67. doi: 10.2165/00002018-200124050-00002. Drug Saf. 2001. PMID: 11419562 Review.

2

Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Jansman FG, Sleijfer DT, Coenen JL, De Graaf JC, Brouwers JR. Jansman FG, et al. Drug Saf. 2000 Oct;23(4):255-78. doi: 10.2165/00002018-200023040-00001. Drug Saf. 2000. PMID: 11051215 Review.

3

Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid.

Jansman FG, Coenen JL, De Graaf JC, Tobi H, Sleijfer DT, Brouwers JR. Jansman FG, et al. Anticancer Res. 2002 Nov-Dec;22(6B):3449-55. Anticancer Res. 2002. PMID: 12552938

4

Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.

Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR. Jansman FG, et al. Clin Ther. 2004 Apr;26(4):579-89. doi: 10.1016/s0149-2918(04)90060-4. Clin Ther. 2004. PMID: 15189755

5

Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.

Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, Brouwers JR. Jansman FG, et al. Clin Ther. 2005 Mar;27(3):327-35. doi: 10.1016/j.clinthera.2005.03.001. Clin Ther. 2005. PMID: 15878386 Clinical Trial.

6

Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer.

Jansman FG, Jansen AJ, Coenen JL, de Graaf JC, Smit WM, Sleijfer DT, Brouwers JR. Jansman FG, et al. Am J Health Syst Pharm. 2005 Sep 1;62(17):1788-93. doi: 10.2146/ajhp040584. Am J Health Syst Pharm. 2005. PMID: 16120738 No abstract available.

7

Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.

Kho Y, Jansman FG, Prins NH, Neef C, Brouwers JR. Kho Y, et al. Among authors: jansman fg. Ther Drug Monit. 2006 Apr;28(2):206-11. doi: 10.1097/01.ftd.0000191305.64775.04. Ther Drug Monit. 2006. PMID: 16628132 Clinical Trial.

8

Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature.

Chedoe I, Molendijk HA, Dittrich ST, Jansman FG, Harting JW, Brouwers JR, Taxis K. Chedoe I, et al. Among authors: jansman fg. Drug Saf. 2007;30(6):503-13. doi: 10.2165/00002018-200730060-00004. Drug Saf. 2007. PMID: 17536876 Review.

9

Cost considerations in the treatment of colorectal cancer.

Jansman FG, Postma MJ, Brouwers JR. Jansman FG, et al. Pharmacoeconomics. 2007;25(7):537-62. doi: 10.2165/00019053-200725070-00002. Pharmacoeconomics. 2007. PMID: 17610336 Review.

10

Pharmacological aspects of neonatal antidepressant withdrawal.

Ter Horst PG, Jansman FG, van Lingen RA, Smit JP, de Jong-van den Berg LT, Brouwers JR. Ter Horst PG, et al. Among authors: jansman fg. Obstet Gynecol Surv. 2008 Apr;63(4):267-79. doi: 10.1097/OGX.0b013e3181676be8. Obstet Gynecol Surv. 2008. PMID: 18348740 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters